BOSTON, Feb. 26, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )) today announced its results for the fourth quarter and full year ended December 31, 2025. The update, including a webcast slide presentation with additional details on the third quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com.
Fourth Quarter 2025 Financial Results
Fourth quarter 2025 Total revenue of $33 million compared to $44 million in the comparable prior year period, Total revenue in the fourth quarter of 2025 decreased 24% from the comparable prior year period.
Fourth quarter 2025 Cell Engineering revenue of $26 million compared to $35 million in the comparable prior year period, a decrease of 26%
Fourth quarter 2025 Biosecurity revenue of $7 million compared to $9 million in the comparable prior year period
Fourth quarter 2025 GAAP net loss of $(81) million, compared to $(108) million in the comparable prior year period
Fourth quarter 2025 Adjusted EBITDA of $(36) million, up from $(57) million in the comparable prior year period, primarily attributable to the decrease in operating expenses in the prior year period
Cash, cash equivalents and marketable securities balance as of December 31, 2025 of $423 million
"This year, we are going to focus on investing to win in the category of autonomous labs," said Jason Kelly, co-founder and CEO of Ginkgo Bioworks. "There is an emerging wave of interest in robotics and AI, and our work with the Department of Energy and OpenAI this year shows that Ginkgo is in the best position to bring robotics to an extraordinarily high value area: laboratory research."
Full Year 2025 Financial Results
Full year 2025 Total revenue of $170 million, down from $227 million in the prior year, a decrease of 25% driven by the shift from early stage customers to large/enterprise customers along with commercial changes related to the restructuring. Full year 2025 and 2024 also benefited from $8 million and $45 million of non-cash revenue from previously announced releases of deferred revenue relating to the mutual terminations of customer agreements.
Full year 2025 Cell Engineering revenue of $133 million, down from $174 million in the prior year, a decrease of 24%. Excluding the non-cash deferred revenue releases discussed above, full year 2025 and 2024 Cell Engineering revenue of $125 million and $129 million, respectively, with 2025 Cell Engineering revenue decreasing 3%, primarily attributed to ongoing program rationalization as part of our restructuring activities. Full year 2025 Biosecurity revenue of $37 million, down from $53 million in the prior year, a decrease of 30%, with full year 2025 Biosecurity gross profit margin of 23%
Full year 2025 GAAP net loss of $(313) million, compared to $(547) million in the prior year
Full year 2025 Adjusted EBITDA of $(167) million, improved from $(293) million in the prior year
Biosecurity Business Divestiture
Ginkgo today announced it has reached an agreement to sell the Company's biosecurity business to a consortium of investors ("Investors") in exchange for a minority equity position in the business alongside the Investors. Upon completion, the biosecurity business will operate as a standalone private entity focused on building a scaled, biosecurity infrastructure platform for the United States and its global partners. The transaction provides the biosecurity business with greater flexibility and additional resources to pursue near- and long-term growth opportunities.
Per Ginkgo CEO Jason Kelly, "There is rising interest in defense tech in private capital markets and spinning off our biosecurity business into a private entity with new investors allows it to grow faster with more investment than it would inside Ginkgo. This serves Ginkgo in two ways: we are able to participate in the upside of the new entity as a shareholder but importantly we also focus Ginkgo's cash investment on our autonomous labs business."
Ginkgo expects to complete the transaction in the first half of 2026, subject to the satisfaction of customary closing conditions.
Recent Business Highlights & Strategic Positioning
We are making 2026 a year of investment in our autonomous lab
This year, we will focus Ginkgo's efforts on autonomous labs as the common platform for biotechnology research and invest to extend our current lead in technology. We are currently expanding our frontier autonomous lab in Boston to include over 50 RACs, with 50 more expected by the end of the year
We will demonstrate the capabilities of autonomous labs by decommissioning the majority of Ginkgo's lab benches, walk-up automation, and workcells and moving our three R&D services businesses onto a single, large autonomous lab
We are commercializing our autonomous lab through two distinct pathways: through our cloud lab services and by building autonomous labs for customers
We just released the results of a collaboration with OpenAI where they used GPT-5 to design experiments using Ginkgo's cloud lab. This resulted in achieving a 40% improvement over the state-of-the-art in Cell-Free Protein Synthesis
After a pilot, we build and install customized autonomous systems directly at customer sites, allowing them to run workflows in a matter of weeks. We did this for the Pacific Northwest National Laboratory, where we recently dedicated an 18-instrument autonomous anaerobic system and won a $47M contract for a 97-instrument autonomous lab
Ginkgo continues to hold a strong cash position while winning new deals across Agriculture, Pharma, and the U.S. Government, providing a strong revenue base to position for future growth
We ended 2025 with $423 million in cash, cash equivalents and marketable securities
Datapoints defined the category of Bio-AI Data Provider, worked with 10 top pharma customers in its first full year.
In the fourth quarter of 2025, Solutions announced partnerships with ARPA-H, University of Illinois Urbana-Champaign, Carnegie Mellon, Agricen, Deep Origin and more
Full Year 2026 Outlook
Ginkgo expects total cash burn of $(150)-$(125) million in 2026.
Conference Call Details
Ginkgo will host a videoconference today, Thursday, February 26, beginning at 4:30 p.m. ET. The presentation will include an overview of the fourth quarter and full year 2025, recent business updates, a discussion on Ginkgo's outlook, as well as a moderated question and answer session.
To ask a question ahead of the presentation, please submit your questions to @Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to [email protected].
A webcast link is available on Ginkgo's Investor Relations website and a replay will be made available following the presentation.
Ginkgo Investor Website: https://investors.ginkgobioworks.com/events/
Audio-Only Dial Ins:
+1 646 876 9923 (New York - ET)+1 301 715 8592 (Washington DC - ET)+1 305 224 1968 (Miami - ET)+1 689 278 1000 (Orlando - ET)+1 312 626 6799 (Chicago - CT)+1 507 473 4847 (Minnesota - CT)+1 346 248 7799 (Houston - CT)+1 719 359 4580 (Colorado - MT)+1 408 638 0968 (San Jose - PT)+1 564 217 2000 (Seattle - PT)Webinar ID: 931 5925 7666
If you experience technical difficulties with any of these dial-ins or if you need international dial-in numbers, please visit our website at https://investors.ginkgobioworks.com/events/ for updated dial-in information.
About Ginkgo BioworksGinkgo Bioworks builds the tools that make biology easier to engineer for everyone. The company offers autonomous laboratories that replace manual laboratory work with robotics in the lab, greatly improving the productivity of scientists. Ginkgo's in-house autonomous lab is also available as a "cloud lab" through our Datapoints and Solutions contract research services. For more information, visit ginkgobioworks.com, read our blog, or follow us on social media channels such as X (@Ginkgo), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.
Forward-Looking Statements of Ginkgo BioworksThis press release, the presentation, and the conference call and webcast contain certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our plans, including with respect to technology adaptations to meet our customers' needs, strategies, including with respect to our current expectations, operations and anticipated results of operations, both business and financial, including the timing for attaining Adjusted EBITDA breakeven, potential customer success, including successful application of our offerings by our customers, expected benefits from our strategic partnerships, and expectations with regard to revenue, including our ability to meet all milestones and achieve the maximum revenue available under certain of our customer arrangements, expenses, our full year 2026 outlook, and the market environment, all of which are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) our ability to realize near-term and long-term cost savings associated with our site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities, (ii) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of our platform programs and assets, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, (x) the product development, production or manufacturing success of our customers, (xi) our exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration we may receive for our services, (xii) the potential negative impact on our business of our restructuring or the failure to realize the anticipated savings associated therewith and (xiii) the uncertainty regarding government budgetary priorities and funding allocated to government agencies, including potential adverse effects from the U.S. government shutdown. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 26, 2026 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.
Use of Non-GAAP Financial MeasuresCertain of the financial measures included in this release, including Adjusted EBITDA, cash flow and cash burn, have not been prepared in accordance with generally accepted accounting principles ("GAAP"), and constitute "non-GAAP financial measures" as defined by the SEC. Ginkgo has included these non-GAAP financial measures because it believes they provide an additional tool for investors to use in evaluating Ginkgo's financial performance and prospects. Due to the nature and/or size of the items being excluded, such items do not reflect future gains, losses, expenses or benefits and are not indicative of our future operating performance. These non-GAAP financial measures are supplemental to, and should not be considered in isolation from, or as an alternative to, financial measures determined in accordance with GAAP. In addition, these non-GAAP financial measures may differ from non-GAAP financial measures with comparable names used by other companies. See the reconciliation below for additional information regarding certain of the non-GAAP financial measures included in this release, including a description of these non-GAAP financial measures and a reconciliation of the historic measures to Ginkgo's most comparable GAAP financial measures.
Ginkgo Bioworks Contacts:
INVESTOR CONTACT:[email protected]
MEDIA CONTACT:[email protected]
Ginkgo Bioworks Holdings, Inc.
Consolidated Balance Sheets
(in thousands, except share data)
As of December 31,
2025
2024
Assets
Current assets:
Cash and cash equivalents
$ 167,202
$ 561,572
Marketable securities
255,418
—
Accounts receivable, net
24,026
21,857
Accounts receivable - related parties
229
586
Prepaid expenses and other current assets
24,963
18,729
Total current assets
471,838
602,744
Property, plant and equipment, net
167,783
203,720
Operating lease right-of-use assets
360,918
394,435
Investments
15,066
48,704
Intangible assets, net
56,924
72,510
Other non-current assets
47,167
55,336
Total assets
$ 1,119,696
$ 1,377,449
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable
$ 10,566
$ 14,169
Deferred revenue (includes $98 and $795 from related parties)
18,946
27,710
Accrued expenses and other current liabilities
66,458
65,387
Total current liabilities
95,970
107,266
Non-current liabilities:
Deferred revenue, net of current portion (includes $64,787 and $72,260 from related parties)
75,182
98,783
Operating lease liabilities, non-current
417,078
438,766
Other non-current liabilities
22,876
16,576
Total liabilities
611,106
661,391
Commitments and contingencies (Note 12)
Stockholders' equity:
Preferred stock, $0.0001 par value; 200,000,000 shares authorized; none issued
—
—
Common stock, $0.0001 par value (Note 13)
6
5
Additional paid-in capital
6,657,053
6,555,416
Accumulated deficit
(6,150,320)
(5,837,557)
Accumulated other comprehensive income (loss)
1,851
(1,806)
Total stockholders' equity
508,590
716,058
Total liabilities and stockholders' equity
$ 1,119,696
$ 1,377,449
The accompanying notes are an integral part of these consolidated financial statements.
Ginkgo Bioworks Holdings, Inc.
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share data)
Year Ended December 31,
2025
2024
2023
Cell Engineering revenue (1)
$ 132,746
$ 173,972
$ 143,531
Biosecurity revenue:
Service
37,409
